All In Biotech

Drug Trial Radar · NCT07365358

Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin

Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Mar 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Chong Kun Dang PharmaceuticalIndustry
Sponsor type
Industry
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Conditions

  • Diabete Type 2

Interventions

  • empagliflozin 10mgDrug

    once a day for 24 weeks

  • Glimepiride 1mgDrug

    once a day for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects who meet 3 conditions at the same timeTime frame: Baseline and Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.